Brokerages expect BioDelivery Sciences International, Inc. (NASDAQ:BDSI) to announce $38.87 million in sales for the current fiscal quarter, according to Zacks Investment Research. Six analysts have issued estimates for BioDelivery Sciences International’s earnings, with estimates ranging from $36.92 million to $40.40 million. BioDelivery Sciences International reported sales of $30.31 million in the same quarter last year, which indicates a positive year over year growth rate of 28.2%. The business is scheduled to issue its next earnings results before the market opens on Thursday, November 5th.
On average, analysts expect that BioDelivery Sciences International will report full-year sales of $154.82 million for the current fiscal year, with estimates ranging from $150.51 million to $159.20 million. For the next year, analysts expect that the business will post sales of $198.31 million, with estimates ranging from $174.99 million to $212.70 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow BioDelivery Sciences International.
BioDelivery Sciences International (NASDAQ:BDSI) last released its earnings results on Wednesday, August 5th. The specialty pharmaceutical company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.03). BioDelivery Sciences International had a return on equity of 17.84% and a net margin of 4.23%. The business had revenue of $36.58 million for the quarter, compared to the consensus estimate of $36.27 million.
A number of brokerages have recently commented on BDSI. Zacks Investment Research cut BioDelivery Sciences International from a “hold” rating to a “sell” rating and set a $4.00 price target for the company. in a research note on Thursday, October 15th. HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of BioDelivery Sciences International in a research note on Thursday, August 6th. Finally, BidaskClub cut BioDelivery Sciences International from a “sell” rating to a “strong sell” rating in a research note on Thursday, October 22nd. Two analysts have rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the stock. BioDelivery Sciences International presently has an average rating of “Hold” and an average price target of $7.91.
Eric Fry, one of America’s top Investment Strategists, provides his latest report 5 Tech Stocks Set for 1,000% Gains after the Coronavirus Sell off. You can’t afford to miss out on the once in a decade chance to buy after the recent dip in the markets.
In other BioDelivery Sciences International news, Director Mark A. Sirgo sold 200,000 shares of the stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $4.74, for a total transaction of $948,000.00. Following the completion of the sale, the director now directly owns 1,206,095 shares in the company, valued at approximately $5,716,890.30. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director W. Mark Watson sold 13,000 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $5.18, for a total value of $67,340.00. Following the sale, the director now owns 217,914 shares of the company’s stock, valued at $1,128,794.52. The disclosure for this sale can be found here. Company insiders own 8.57% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of the company. Raymond James & Associates grew its stake in shares of BioDelivery Sciences International by 6.8% in the 3rd quarter. Raymond James & Associates now owns 64,486 shares of the specialty pharmaceutical company’s stock valued at $241,000 after buying an additional 4,100 shares during the period. Los Angeles Capital Management & Equity Research Inc. grew its stake in shares of BioDelivery Sciences International by 17.6% in the 3rd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 787,244 shares of the specialty pharmaceutical company’s stock valued at $2,936,000 after buying an additional 117,735 shares during the period. BNP Paribas Arbitrage SA grew its stake in shares of BioDelivery Sciences International by 546.8% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 20,703 shares of the specialty pharmaceutical company’s stock valued at $77,000 after buying an additional 17,502 shares during the period. Exane Derivatives grew its stake in shares of BioDelivery Sciences International by 103.8% in the 3rd quarter. Exane Derivatives now owns 10,923 shares of the specialty pharmaceutical company’s stock valued at $41,000 after buying an additional 5,563 shares during the period. Finally, Hikari Power Ltd bought a new position in BioDelivery Sciences International in the 3rd quarter valued at about $93,000. Institutional investors own 70.21% of the company’s stock.
NASDAQ BDSI opened at $3.46 on Thursday. BioDelivery Sciences International has a fifty-two week low of $2.85 and a fifty-two week high of $7.21. The stock has a market capitalization of $349.23 million, a PE ratio of 69.20 and a beta of 0.63. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.81 and a quick ratio of 2.49. The business has a fifty day moving average price of $3.69 and a two-hundred day moving average price of $4.26.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug-delivery technologies.
Recommended Story: How Investors Use a Balance Sheet
Get a free copy of the Zacks research report on BioDelivery Sciences International (BDSI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Portfolio
Almost everyone loves a company that pays strong dividends. Who doesn’t like receiving a check every quarter for simply owning a stock–especially if that stock is paying you back 4%, 5% or even 10% of its share price in annual income each year?. In a world where 10-year treasuries are yielding just above 2%, it seems hard to go wrong when buying a stock that’s yielding significantly above the going rates on fixed-income assets. Unfortunately, the market rarely offers a free lunch.
While high-yield stocks may have a lot of near-term attractiveness, those same high-yields can often signal significant danger ahead. In some cases, it might mean that the company’s dividend will stop growing or won’t grow as fast as it used to. Worse yet, the company could cut its dividend, reduce the income you receive from owning the stock and drive down the value of the shares that you own.
4%-plus yields might seem like an easy opportunity to boost the investment income you receive, but high-yield stocks can just as often be a track reading to snare unsuspecting investors. It’s not always easy to tell the difference though.
This slideshow highlights 10 high-yield dividend stocks that are paying an unsustainably large percentage of their earnings in the form of a dividend. These companies are all paying out more than 100% of their earnings per share in the form of a dividend, a sign that the advertised high-yield probably won’t last.
View the “20 High-Yield Dividend Stocks that Could Ruin Your Retirement Portfolio”.
